Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
Maqola

Developing antineoplastic agents that target peroxisomal enzymes: cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4)

M. S. FrasinyukCollege of MedicineWen ZhangCollege of MedicinePrzemysław WyrębekCollege of MedicineTianxin YuCollege of MedicineXuehe XuCollege of MedicineVitaliy M. SviripaCenter for Pharmaceutical Research and InnovationS. P. BondarenkoKyivYanqi XieCollege of MedicineHuy NgoCollege of PharmacyAndrew J. MorrisCollege of MedicineJames L. MohlerBuffaloMichael V. FiandaloBuffaloDavid S. WattCollege of MedicineChunming LiuCollege of Medicine
2017en
ABI

Annotatsiya

Cytisine-linked isoflavonoids (CLIFs) inhibited PC-3 prostate and LS174T colon cancer cell proliferation by inhibiting a peroxisomal bifunctional enzyme. A pull-down assay using a biologically active, biotin-modified CLIF identified the target of these agents as the bifunctional peroxisomal enzyme, hydroxysteroid 17β-dehydrogenase-4 (HSD17B4). Additional studies with truncated versions of HSD17B4 established that CLIFs specifically bind the C-terminus of HSD17B4 and selectively inhibited the enoyl CoA hydratase but not the d-3-hydroxyacyl CoA dehydrogenase activity. HSD17B4 was overexpressed in prostate and colon cancer tissues, knocking down HSD17B4 inhibited cancer cell proliferation, suggesting that HSD17B4 is a potential biomarker and drug target and that CLIFs are potential probes or therapeutic agents for these cancers.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba